Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Jan-Niklas Eckardt, Ishan Srivastava, Yeqiao Xu, Kellen B Gil, Andrea A. Osypuk, Zenggang Pan, Martin M. K. Schneider, Freya Schulze, Karsten Wendt, Susann Winter, Martin Bornhäuser, Daniel A. Pollyea, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2024-206776

Published: 2024

Journal Articles

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Jan-Niklas Eckardt, Ishan Srivastava, Zizhe Wang, Susann Winter, Tim Schmittmann, Sebastian Riechert, Miriam Eva Helena Gediga, Anas Shekh Sulaiman, Martin M. K. Schneider, Freya Schulze, Christian Thiede, Katja Sockel, Frank P. Kroschinsky, Christoph Röllig, Martin Bornhäuser, Karsten Wendt, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 1057.

https://doi.org/10.1182/blood-2024-198486

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Journal Articles

Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Dante Adami, Sebastian Riechert, Tim Schmittmann, Markus Badstübner, Karsten Wendt, Stefani Barbara Parmentier, Katja Sockel, Frank P. Kroschinsky, Martin Bornhäuser, Jan Moritz Middeke, Jan-Niklas Eckardt

Blood (2024) 144 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2024-205235

Published: 2024

Journal Articles

Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms

Freya Schulze, Waldemar Hahn, Katja Sockel, Susann Winter, Markus Wolfien, Martin Bornhaeuser, Jan Moritz Middeke, Jan-Niklas Eckardt

Blood (2024) 144 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2024-210870

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Automated Preselection of Regions of Interest By Deep Learning Facilitates Rapid Whole Slide Image Analysis of Bone Marrow Smears

Martin M. K. Schneider, Freya Schulze, Tim Schmittmann, Sebastian Riechert, Miriam Eva Helena Gediga, Katja Sockel, Frank P. Kroschinsky, Karsten Wendt, Martin Bornhaeuser, Jan Moritz Middeke, Jan-Niklas Eckardt

Blood (2023) 142 (Supplement 1): 3662.

https://doi.org/10.1182/blood-2023-187501

Published: 2023

Journal Articles

Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies

Johannes Schetelig, Henning Baldauf, Carina Rave, Gesine Bug, Lutz Peter Hermann Mueller, Eva Wagner Drouet, Francis A. Ayuk, Wolfgang Andreas Bethge, Matthias Stelljes, Thomas Schröder, Desiree Kunadt, Katja Sockel, Jan Moritz Middeke, Daniel Fürst, Alexander H. Schmidt, Katharina Fleischhauer, Martin Bornhäuser

Blood (2023) 142 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2023-180531

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Adolfo De La Fuente Burguera, Claudio Cerchione, Sebastian Scholl, Jan Moritz Middeke, Gaurav S Choudhary, Reinhard von Roemeling, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 5975.

https://doi.org/10.1182/blood-2023-190125

Published: 2023

Journal Articles

Explainable End-to-End Supervised Learning Identifies Myelodysplastic Neoplasms in Bone Marrow Smears

Jan-Niklas Eckardt, Tim Schmittmann, Freya Schulze, Sebastian Riechert, Martin M. K. Schneider, Lukas Reichel, Miriam Eva Helena Gediga, Katja Sockel, Anas Shekh Sulaiman, Ekaterina Balaian, Christoph Röllig, Frank P. Kroschinsky, Anne Marie Asemissen, Uwe Platzbecker, Christian Pohlkamp, Torsten Haferlach, Karsten Wendt, Martin Bornhäuser, Jan Moritz Middeke

Blood (2023) 142 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2023-185628

Published: 2023

Journal Articles

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, Sebastian Stasik, Uwe Platzbecker, Carsten Müller-Tidow, Hubert Serve, Claudia D Baldus, Christoph Schliemann, Kerstin Schäfer-Eckart, Maher Hanoun, Martin Kaufmann, Andreas Burchert, Christian Thiede, Johannes Schetelig, Martin Bornhäuser, Markus Wolfien, Jan Moritz Middeke

Blood (2023) 142 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2023-179817

Published: 2023

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Journal Articles

Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Gerhard Ehninger, Sabrina Kraus, Elisa Sala, Stephan K Metzelder, Vladan Vucinic, Walter Fiedler, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Malte von Bonin, Carla Kreissig, Jan Koedam, Marc Cartellieri, Armin Ehninger, Martin Wermke, Jonas A. Schäfer

Blood (2022) 140 (Supplement 1): 2367–2368.

https://doi.org/10.1182/blood-2022-168877

Published: 2022

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Blood (2022) 140 (Supplement 1): 3327–3328.

https://doi.org/10.1182/blood-2022-159897

Published: 2022

NARROW

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Automated Preselection of Regions of Interest By Deep Learning Facilitates Rapid Whole Slide Image Analysis of Bone Marrow Smears

Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Explainable End-to-End Supervised Learning Identifies Myelodysplastic Neoplasms in Bone Marrow Smears

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only